AMCP applauds the introduction of the Access to Prescription Digital Therapeutics Act of 2023 into the Senate and House by a bipartisan group of Senators and Representatives. The bill would authorize coverage of prescription digital therapeutics by Medicare and Medicaid, helping millions of Americans receive innovative care to treat a growing range of conditions and illnesses.
With changing industry trends and new legislation, having robust Real World Evidence (RWE) for your organization is more important than ever. In this sponsored webinar, leaders at the forefront of healthcare discuss their experiences with regulatory submissions and selecting quality data.
On March 6, AMCP submitted a comment letter in response to the Centers for Medicare and Medicaid Services' Advance Notice of Methodological Changes for Calendar Year (CY) 2024 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies. AMCP's comments support CMS' proposed Universal Foundation and commitment to advancing health equity, as well as the use of inclusive and gender-affirming approaches to HEDIS measures.
On March 3, AMCP joined 11 other pharmacy associations in a sign-on letter addressing pharmacy priorities following the end of the COVID-19 Public Health Emergency (PHE) in May. The letter, addressed to HHS Secretary Xavier Becerra and White House COVID-19 Response Coordinator Dr. Ashish Jha, requests the Administration take immediate action to ensure continued access to certain critical patient care services delivered by pharmacists under the COVID-19 PHE.
The product review process is complex and can vary between organizations. Join us as our expert panel outlines best practices for conducting a comprehensive product review. Our panel represents the managed care organization and biopharma company viewpoints to discuss current challenges and opportunities to streamline the product review process; including ways to incorporate digital tools.